Peptide Comparison
Immunoxel (Dzherelo)vsThymosin Alpha-1
Ukrainian botanical immunomodulator that supercharges tuberculosis treatment and restores immune function in HIV patients
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
At a Glance
Quick
comparison
Dose Range
Immunoxel (Dzherelo)
25–50 drops
Thymosin Alpha-1
1.6–3.2 mg
Frequency
Immunoxel (Dzherelo)
Multiple times daily
Thymosin Alpha-1
Twice weekly
Administration
Immunoxel (Dzherelo)
Oral (liquid drops)
Thymosin Alpha-1
Subcutaneous injection
Cycle Length
Immunoxel (Dzherelo)
8-12 weeks
Thymosin Alpha-1
8-12 weeks
Onset Speed
Immunoxel (Dzherelo)
Moderate (1-2 weeks)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence Level
Immunoxel (Dzherelo)
Moderate human trials (Phase 1-2)
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
TB Treatment Enhancement
Immune Restoration
Infection Prevention
Immune Activation
Infection Fighting
Immune Balance
Technical Data
Compound
specifications
Immunoxel (Dzherelo)
Molecular Formula
N/A — multi-component herbal phytoconcentrate
Molecular Weight
N/A — complex botanical mixture of multiple plant compounds
Half-Life
Not precisely characterized; immunomodulatory effects develop over days to weeks of consistent dosing
Bioavailability
Good oral and sublingual bioavailability; sublingual lozenges shown equivalent to twice-daily oral liquid
CAS Number
Proprietary combination
Thymosin Alpha-1
Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
Half-Life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS Number
62304-98-7
Protocols
Dosing
tiers
Immunoxel (Dzherelo)
Thymosin Alpha-1
Applications
Best
suited for
Immunoxel (Dzherelo)
Tuberculosis Adjunct Treatment
Immunoxel's strongest evidence is as an add-on to standard TB drugs. A meta-analysis of 6 clinical trials found patients receiving Immunoxel were 3.19 times more likely to become sputum-negative compared to TB drugs alone. In one study, 84.1% of patients converted within 1 month versus only 19% on placebo.
HIV/TB Coinfection Immune Support
For patients battling both HIV and TB simultaneously, Immunoxel offers remarkable immune benefits. Clinical trials showed CD4+ T-cell counts increased by 71.2% in just 2 months, viral load decreased significantly, and opportunistic infections dropped from 12 episodes to just 3 compared to standard therapy alone.
Drug-Resistant Tuberculosis Support
Immunoxel has been studied in multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) patients where standard treatments often struggle. Its immune-boosting effects help the body fight TB even when the bacteria resist front-line drugs.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety Profile
Side
effects
Immunoxel (Dzherelo)
Common
- Well-tolerated in most patients
- Mild gastrointestinal discomfort
Uncommon
- Temporary taste changes
- Mild allergic skin reactions
- Mild headache
Serious
- Potential herb-drug interactions
Thymosin Alpha-1
Common
- Injection site reactions
- Mild fatigue
- Flu-like symptoms
Uncommon
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Immunoxel (Dzherelo)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature.
Contraindications
- xKnown hypersensitivity to any of the plant ingredients in the formulation
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere liver disease (contains alcohol-based extract)
- xUse as sole therapy for TB or HIV (must be combined with standard treatment)
Thymosin Alpha-1
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for other use
Safety Overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- xOrgan transplant recipients on immunosuppressants
- xActive autoimmune disease flares
- xKnown allergy to thymosin peptides
- xPregnancy or breastfeeding
- xChildren under 18 without medical supervision
Decision Guide
Which is
right for you?
Choose Immunoxel (Dzherelo) if...
- Adjunct immunotherapy alongside tuberculosis treatment
- Immune restoration in HIV/TB coinfected patients
- Reducing opportunistic infection rates
- Supporting overall immune function during infectious disease treatment
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support